Piper Sandler Begins Coverage of Danaher (DHR) While Waiting for New Growth Catalysts

Danaher Corporation (NYSE:DHR) is included among Billionaire Larry Robbins’ 10 Dividend Stock Picks.

Piper Sandler Begins Coverage of Danaher (DHR) While Waiting for New Growth Catalysts

On June 11, Piper Sandler initiated coverage of Danaher Corporation (NYSE:DHR) with a Neutral rating and a $200 price target. The firm launched coverage of the life science tools sector with what it described as a “feet in the shallow end of the pool” approach. Among the companies under coverage, Piper only recommends buying Twist Bioscience, citing its growing exposure to next-generation drug discovery and development.

According to the analyst, headwinds related to biotech and academic spending, along with China exposure, are likely to improve in the near term. Even so, Piper wants to see some of the next major growth drivers emerge before recommending more stocks in the sector. The firm argues that investors “can buy multi-year growth compounding stocks early, middle, and late into their growth cycles but would simply prefer to wait out a couple quarters for the sector to perform like it did pre-COVID.”

Danaher Corporation (NYSE:DHR) is a global life sciences and diagnostics innovator. The company operates through three segments: Biotechnology, Life Sciences, and Diagnostics.

While we acknowledge the risk and potential of DHR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than DHR and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best S&P 500 Dividend Stocks to Buy Right Now and 10 Best Value Dividend Stocks to Buy Now According to Warren Buffett

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1